Abstract
Drug development is a resource-intensive process requiring significant financial and time investment. Preclinical target validation studies and in vivo testing of the therapeutic molecules in clinically relevant disease models can accelerate and significantly de-risk later stage clinical development. In this chapter, we will focus on (1) in vivo animal models and (2) pharmacological tools for target validation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bahou WF, Bowie EJ, Fass DN, Ginsburg D (1988) Molecular genetic analysis of porcine von Willebrand disease: tight linkage to the von Willebrand factor locus. Blood 72:308–313
Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr (1995) Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10:119–121
Bogue MA, Grubb SC (2004) The mouse phenome project. Genetica 122:71–74
Booth CJ, Brooks MB, Rockwell S et al (2010a) WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost 8:2472–2477
Booth CJ, Brooks MB, Rockwell S (2010b) Spontaneous coagulopathy in inbred WAG/RijYcb rats. Comp Med 60:25–30
Brinkhous KM, Graham JB (1950) Hemophilia in the female dog. Science 111:723–724
Brooks AR, Sim D, Gritzan U et al (2013) Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy. J Thromb Haemost 11:1699–1706
C. elegans Sequencing Consortium (1998) Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282:2012–2018
Cook N, Jodrell DI, Tuveson DA (2012) Predictive in vivo animal models and translation to clinical trials. Drug Discov Today 17:253–260
Crudele JM, Finn JD, Siner JI et al (2015) AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125:1553–1561
Denis C, Methia N, Frenette PS et al (1998) A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A 95:9524–9529
Drummond IA (2005) Kidney development and disease in the zebrafish. J Am Soc Nephrol 16:299–304
Dumont JA, Liu T, Low SC et al (2012) Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 119:3024–3030
Elm T, Karpf DM, Ovlisen K et al (2012) Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia 18:139–145
Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA (1989) Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A 86:10095–10099
Fass DN, Bowie EJ, Owen CA Jr, Zollman PE (1979) Inheritance of porcine von Willebrand’s disease: study of a kindred of over 700 pigs. Blood 53:712–719
Felix MA, Braendle C (2010) The natural history of Caenorhabditis elegans. Curr Biol 20:050
Furth PA, St Onge L, Boger H et al (1994) Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 91:9302–9306
Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397–405
Garza JC, Kim CS, Liu J, Zhang W, Lu XY (2008) Adeno-associated virus-mediated knockdown of melanocortin-4 receptor in the paraventricular nucleus of the hypothalamus promotes high-fat diet-induced hyperphagia and obesity. J Endocrinol 197:471–482
Giles AR, Tinlin S, Greenwood R (1982) A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60:727–730
Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH (1980) Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci U S A 77:7380–7384
Graham JB, Buckwalter JA et al (1949) Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med 90:97–111
Grubb SC, Churchill GA, Bogue MA (2004) A collaborative database of inbred mouse strain characteristics. Bioinformatics 20:2857–2859
Grubb SC, Bult CJ, Bogue MA (2014) Mouse phenome database. Nucleic Acids Res 42:D825–D834
Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR (2005) Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 105:145–152
Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40–51
Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 169:59–72
Howe K, Clark MD, Torroja CF et al (2013) The zebrafish reference genome sequence and its relationship to the human genome. Nature 496:498–503
Hsieh CS, Macatonia SE, O’Garra A, Murphy KM (1995) T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 181:713–721
Kashiwakura Y, Mimuro J, Onishi A et al (2012) Porcine model of hemophilia A. PLoS One 7:28
Kirienko NV, Mani K, Fay DS (2010) Cancer models in Caenorhabditis elegans. Dev Dyn 239:1413–1448
Kistner A, Gossen M, Zimmermann F et al (1996) Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93:10933–10938
Koller BH, Hagemann LJ, Doetschman T et al (1989) Germ-line transmission of a planned alteration made in a hypoxanthine phosphoribosyltransferase gene by homologous recombination in embryonic stem cells. Proc Natl Acad Sci U S A 86:8927–8931
Kucherlapati R (2012) Genetically modified mouse models for biomarker discovery and preclinical drug testing. Clin Cancer Res 18:625–630
Leong L, Sim D, Patel C et al (2015) Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models. Blood 125:392–398
Li J, Le W (2013) Modeling neurodegenerative diseases in Caenorhabditis elegans. Exp Neurol 250:94–103
Li TT, Larrucea S, Souza S et al (2004) Genetic variation responsible for mouse strain differences in integrin alpha 2 expression is associated with altered platelet responses to collagen. Blood 103:3396–3402
Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90:3962–3966
Lin CN, Kao CY, Miao CH et al (2010) Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 8:1773–1783
Liu S, Leach SD (2011) Zebrafish models for cancer. Annu Rev Pathol 6:71–93
Mauser AE, Whitlark J, Whitney KM, Lothrop CD Jr (1996) A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood 88:3451–3455
McIntosh J, Lenting PJ, Rosales C et al (2013) Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121:3335–3344
Mei B, Pan C, Jiang H et al (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 116:270–279
Menoret S, Fontaniere S, Jantz D et al (2013) Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases. FASEB J 27:703–711
Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 102:634–644
Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166–6173
Mustard JF, Rowsell HC, Robinson GA, Hoeksema TD, Downie HG (1960) Canine haemophilia B (Christmas disease). Br J Haematol 6:259–266
Neuenschwander S, Kissling-Albrecht L, Heiniger J, Backfisch W, Stranzinger G, Pliska V (1992) Inherited defect of blood clotting factor VIII (haemophilia A) in sheep. Thromb Haemost 68:618–620
Novoa B, Figueras A (2012) Zebrafish: model for the study of inflammation and the innate immune response to infectious diseases. Adv Exp Med Biol 946:253–275
Ostergaard H, Bjelke JR, Hansen L et al (2011) Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118:2333–2341
Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B (2012) A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate((R))). Haemophilia 18:782–788
Pastoft AE, Ezban M, Tranholm M, Lykkesfeldt J, Lauritzen B (2013) Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. Haemophilia 19:913–919
Peng A, Straubinger RM, Balu-Iyer SV (2010) Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 12:473–481
Peters RT, Low SC, Kamphaus GD et al (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115:2057–2064
Platt RJ, Chen S, Zhou Y et al (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440–455
Porada CD, Sanada C, Long CR et al (2010) Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost 8:276–285
Rubinson DA, Dillon CP, Kwiatkowski AV et al (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401–406
Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988) Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168:1675–1684
Spence R, Gerlach G, Lawrence C, Smith C (2008) The behaviour and ecology of the zebrafish, Danio rerio. Biol Rev Camb Philos Soc 83:13–34
Stennicke HR, Kjalke M, Karpf DM et al (2013) A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 121:2108–2116
Stewart D, Fulton WB, Wilson C et al (2002) Genetic contribution to the septic response in a mouse model. Shock 18:342–347
Sun N, Zhao H (2013) Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioeng 110:1811–1821
Tang K, Rossiter HB, Wagner PD, Breen EC (2004) Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. J Appl Physiol 97:1559–1566, discussion 1549
Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:636–646
Ventura A, Meissner A, Dillon CP et al (2004) Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 101:10380–10385
Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM (1997) A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 94:11563–11566
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Sim, D.S., Kauser, K. (2015). In Vivo Target Validation Using Biological Molecules in Drug Development. In: Nielsch, U., Fuhrmann, U., Jaroch, S. (eds) New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, vol 232. Springer, Cham. https://doi.org/10.1007/164_2015_17
Download citation
DOI: https://doi.org/10.1007/164_2015_17
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28912-0
Online ISBN: 978-3-319-28914-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)